---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-099101"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T11:37:12.467068+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gilead settles patent litigation for Descovy, Vemlidy, Odefsey; generic licenses begin 2031-2032

## Summary
- Agreements with Lupin, Apotex, Macleods, Hetero, Cipla resolve patent challenges for HIV drugs.
- License for Descovy and Vemlidy begins Oct 31, 2031; for Odefsey begins Jan 31, 2032, with earlier entry possible.
- Agreements filed with FTC and DOJ; dismissals filed in Delaware district court.
- Settlement removes litigation uncertainty but establishes generic entry timeline for key HIV portfolio.

## SEC filing metadata
- accession: 0001104659-22-099101
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465922099101/0001104659-22-099101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465922099101/tm2225634d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-099101
- JSON: https://secwatch.observer/filing/0001104659-22-099101.json
- Plain text: https://secwatch.observer/filing/0001104659-22-099101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.